Standard
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. / Barratt, Daniel T; Bandak, Benedikte; Klepstad, Pål; Dale, Ola; Kaasa, Stein; Christrup, Lona Louring; Tuke, Jonathan; Somogyi, Andrew A.
In:
Pharmacogenetics and Genomics, Vol. 24, No. 4, 2014, p. 185-194.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Barratt, DT, Bandak, B, Klepstad, P, Dale, O, Kaasa, S
, Christrup, LL, Tuke, J & Somogyi, AA 2014, '
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study',
Pharmacogenetics and Genomics, vol. 24, no. 4, pp. 185-194. <
http://journals.lww.com/jpharmacogenetics/Abstract/2014/04000/Genetic,_pathological_and_physiological.1.aspx>
APA
Barratt, D. T., Bandak, B., Klepstad, P., Dale, O., Kaasa, S.
, Christrup, L. L., Tuke, J., & Somogyi, A. A. (2014).
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
Pharmacogenetics and Genomics,
24(4), 185-194.
http://journals.lww.com/jpharmacogenetics/Abstract/2014/04000/Genetic,_pathological_and_physiological.1.aspxVancouver
Barratt DT, Bandak B, Klepstad P, Dale O, Kaasa S, Christrup LL et al. Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics. 2014;24(4):185-194.
Author
Barratt, Daniel T ; Bandak, Benedikte ; Klepstad, Pål ; Dale, Ola ; Kaasa, Stein ; Christrup, Lona Louring ; Tuke, Jonathan ; Somogyi, Andrew A. / Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. In: Pharmacogenetics and Genomics. 2014 ; Vol. 24, No. 4. pp. 185-194.
Bibtex
@article{05697880dc1a46589cbc1af79da501d5,
title = "Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study",
abstract = "This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl.",
author = "Barratt, {Daniel T} and Benedikte Bandak and P{\aa}l Klepstad and Ola Dale and Stein Kaasa and Christrup, {Lona Louring} and Jonathan Tuke and Somogyi, {Andrew A}",
year = "2014",
language = "English",
volume = "24",
pages = "185--194",
journal = "Pharmacogenetics",
issn = "1744-6872",
publisher = "Lippincott Williams & Wilkins",
number = "4",
}
RIS
TY - JOUR
T1 - Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study
AU - Barratt, Daniel T
AU - Bandak, Benedikte
AU - Klepstad, Pål
AU - Dale, Ola
AU - Kaasa, Stein
AU - Christrup, Lona Louring
AU - Tuke, Jonathan
AU - Somogyi, Andrew A
PY - 2014
Y1 - 2014
N2 - This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl.
AB - This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl.
M3 - Journal article
C2 - 24469018
VL - 24
SP - 185
EP - 194
JO - Pharmacogenetics
JF - Pharmacogenetics
SN - 1744-6872
IS - 4
ER -
